inforMD Genomics is our solution that provides physicians the testing capabilities to address early detection in their practice. Supported by a team of world leading scientists and researchers who provide education, interpretation and consultation, our lab partners across the country continue to create unique tests to help us better understand the over 3 billion letters of our genetic code. Allow us to share with you how our Genomics platform can enhance the performance of your practice and improve your patient outcomes.
Cancer screenings are the beginning of prevention, diagnosis and treatment of diseases. As a medical provider, you want to improve the lives of your patients while maintaining their quality of life. Our laboratory partner’s hereditary cancer test panels analyze the most frequent syndromes that present predisposition to cancer. These panels cover an analysis of 31 genes associated with the diseases, increasing the accuracy of diagnosis and treatment. Early diagnosis based on preventive tests is highly important and can save a patient’s life.
A non-invasive genetic screen that provides data to aid providers in determining the patient’s risk profile for developing eight genetically linked cancers.
Blood screenings provide a comprehensive evaluation of a general health status for patients. Patients expect personalized care, tailored medications and thoughtful oversight. A blood chemistry screen is commonly used as an initial test to indicate potential health problems in patients. Our laboratory partners’ testing panels give a detailed analysis of any disease markers, nutrients and waste products in the blood, as well as how various organs are functioning.
Successful pain management effectively controls patient pain without causing excess side effects from prescribed medications. Acknowledging that each patient responds differently to drugs and knowing that drugs are often the first choice of treatment for pain, pharmacogenetic testing can protect the well-being of patients, practices and medical providers. Physicians will know with certainty how patients will metabolize pharmaceuticals and the appropriate substitutions where necessary. Our partner laboratory provides an analysis of the patient’s genetic response to a specific drug for each drug tested. The goal of these results could be used to optimize drug choice and/or dose earlier for a more effective therapy.
The Cardiovascular Genetics Test panel is a comprehensive next-generation sequencing-based molecular test for inherited cardiovascular diseases. This panel includes all genes associated or potentially associated with the development of inherited cardiovascular diseases that can present sudden death as a major adverse event. The test detects genomic variations in 213 genes related to cardiovascular diseases and provides cardiologists and other physician specialists with clear genetic interpretation for risk assessment and disease diagnosis.